Nexstim Receives Order for Two NBT® Systems from Finnish University Hospital Customer
Press release, Helsinki, December 10, 2021 at9 AM(EET)
Nexstim Receives Order for Two NBT® Systems from Finnish University Hospital Customer
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an order for two NBT® systems from a university hospital in Finland.
The hospital has strong experience in using Nexstim systems and is now increasing its resources to be able to treat more patients. The Nexstim NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to have seenstrong interest in our products among both existing and new customers this year.It is with great excitement that we have received this order for two newNBT® systems from this university hospital.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.nexstim.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DNO Receives 10 Awards in Norway's APA Licensing Round18.1.2022 15:54:11 CET | Press release
Oslo, 18 January 2022 – DNO ASA, the Norwegian oil and gas operator, today announced that its wholly-owned subsidiary DNO Norge AS has been awarded participation in 10 exploration licenses, of which three are operatorships, under Norway's Awards in Predefined Areas (APA) 2021 licensing round. Of the 10 new licenses, six are in the North Sea and four in the Norwegian Sea. At yearend 2021, DNO held interests in 73 licenses offshore Norway, of which 17 were operated by the Company. The new awards under the APA 2021 licensing round include: PL 586 B: Neptune Energy Norge AS (operator), Suncor Energy Norge AS, Vår Energi AS, DNO Norge AS (7.5%) PL 923 B: Equinor Energy AS (operator), Petoro AS, Wellesley Petroleum AS, DNO Norge AS (20%) PL 969 B: A/S Norske Shell (operator), Spirit Energy Norway, DNO Norge AS (45%) PL 1007 B: DNO Norge AS (operator, 40%), OMV (Norge) AS, Equinor Energy AS, Spirit Energy Norway AS PL 1145: DNO Norge AS (operator, 60%), Aker BP ASA PL 1146: ConocoPhillips Ska
AGC Biologics Names Regina Choi-Rivera New General Manager of Boulder, Colorado Mammalian Production Facility18.1.2022 15:05:00 CET | Press release
Boulder, Colo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations. “We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.” Ms. Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsun
Solidium’s CEO to change18.1.2022 14:01:05 CET | Press release
Solidium’s CEO, Antti Mäkinen, will leave his position as the CEO of Solidium on 31st May 2022. Mäkinen, 60, has acted as CEO of the company since year 2017. “The past five years have been rewarding and I have had the opportunity to work with an excellent team and great portfolio companies. Solidium has an established position and a strong track in growing shareholder value”, says Mäkinen. Antti Mäkinen has acted as a Board Member and Chairman of the Shareholders’ Nomination Committee in many of Solidium’s portfolio companies. He is still nominated this Spring in the Annual General Meetings i.a. as the Chairman of the Board in Stora Enso and a Member of the Board in Metso Outotec. The Chairman of the Board of Solidium, Harri Sailas, would like to thank Mäkinen for his work both in charge of Solidium and as Solidium’s representative in the portfolio companies. “In Antti Mäkinen’s steering, Solidiums position has stabilized and the company has been more active both as an owner and in mak
Solidiums verkställande direktör avgår18.1.2022 14:01:05 CET | Pressemelding
Solidiums verkställande direktör Antti Mäkinen lämnar sin post som VD den 31 maj 2022. Mäkinen, 60, har verkat i företagets ledning från och med år 2017. ”De senaste fem åren har varit givande och jag har fått arbeta med ett utmärkt team och fina portföljbolag. Solidium har en stabil position och bevisad förmåga att öka innehavens ägarvärde”, säger Mäkinen. Antti Mäkinen har verkat i flera av Solidiums portföljbolag som styrelsemedlem och som ordförande i aktieägarnas nomineringskommitté. Han är fortfarande nominerad i vårens bolagsstämmor bland annat som styrelseordförande i Stora Enso och styrelsemedlem i Metso Outotec. Solidiums styrelseordförande Harri Sailas tackar Mäkinen för arbetet både inom Solidiums ledning och som representant i Solidiums portföljbolag. ”Under ledning av Antti Mäkinen har Solidiums position etablerat sig och företaget har aktiverat sig både som ägare och vid att göra nya placeringar. Hans agerande har väckt uppskattning i alla företagets intressegrupper”, sä
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.1.2022 11:30:00 CET | Press release
AuctionAuction resultsAuction date2022-01-18Maturity2024Tendered volume, SEK mln750 +/- 750Offered volume, SEK mln1593Volume bought, SEK mln1500Number of bids19Number of accepted bids19 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln720205600Volume bought, SEK mln627205600Number of bids4310Number of accepted bids4310Average DM-0.166-0.139-0.129-Lowest accepted DM-0.179-0.160-0.129-Highest DM-0.129-0.139-0.129-Accepted at lowest DM0.814100.00100.00- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln4081001000Volume bought, SEK mln4081001000Number of bids7310Number of accepted bids7310Average DM-0.133-0.129-0.140-Lowest accepted DM-0.160-0.129-0.140-Highest DM-0.120-0.129-0.140-Accepted at lowest DM100.00100.00100.00-
Aspo subsidiary ESL Shipping continues fleet renewal in accordance with its strategy by selling the barge Espa18.1.2022 11:15:00 CET | Press release
Aspo Plc Press Release January 18, 2022, at 12.15 p.m. Aspo subsidiary ESL Shipping continues fleetrenewal in accordance with its strategy by selling the barge Espa Aspo’s ESL Shipping continues fleet renewal by selling its smallest, 9000 dwt towable barge Espa to Raduga Shipping and Trading OÜ. The transaction was concluded and Espa subsequently delivered to her new owner today 18th of January. A sales gain of approximately 1.4 million euros will be recorded in the profit of ESL Shipping’s first quarter. Espa was built in 1987 as the last vessel of the Vuosaari shipyard in Helsinki. She was designed and equipped for efficient transportation and lightering of energy coal cargoes to powerplants in Helsinki. In recent years she was mainly used for cement industry transport demand. She also spent one summer as a floating beach volley field in Helsinki. Peculiarities in Finnish shipping policy led to increasing cost of barge towing tugboats, as tugboat crew could not receive state support
RESULT OF RIKSBANK CERTIFICATE SALE18.1.2022 10:15:00 CET | Press release
AuctionAuction resultsAuction date2022-01-18Start date2022-01-19Maturity date2022-01-26Interest rate, %0.00Offered volume, SEK bn570.0Total bid amount, SEK bn2737.4Accepted volume, SEK bn570.0Number of bids16Percentage alloted, %20.823